The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

An oral melanocortin-4 receptor agonist conferred significant BMI reductions among adolescents and adults with hypothalamic ...

Mike Vaccaro Leon Rose upgrading Knicks depth chart comes with dose of Tom Thibodeau ‘irony’ By Mike Vaccaro Published July 1, 2025, 7:58 p.m. ET ...

In this phase, patients received open-label rivastigmine. Those patients who chose to enter the open-label phase with rivastigmine after progression to AD received dose titration from a starting dose ...

The changes in the dose chart were based on the introduction of new entities (eg, mometasone furoate), as well as significant formulation changes of older drugs (eg, beclomethasone dipropionate ...

Consequently, combination therapy currently involves the administration of one cholinergic drug (donepezil, galantamine or rivastigmine) and one glutamatergic drug (memantine).